Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer

Lebret, T.; Rouanne, Mathieu; Hublarov, O.; Jinga, Viorel; Petkova, L.; Kotsev, R; Sinescu, I.; Dutailly, Pascale

doi:10.1177/1756287215577329

Cited by 10 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients are also offered greater flexibility by the availability of subcutaneous (SC) injections of triptorelin [ 31 ]. The IM route of administration may not be suitable for all patients (for example, the risk of excessive bleeding or haematomas in those receiving anticoagulants) [ 32 ], and so SC injections provide an alternative delivery option.…”

Section: Triptorelin As Adtmentioning

confidence: 99%

“…The IM route of administration may not be suitable for all patients (for example, the risk of excessive bleeding or haematomas in those receiving anticoagulants) [ 32 ], and so SC injections provide an alternative delivery option. The key pharmacokinetic parameters (such as C max and C min ) with the SC injection of a triptorelin pamoate 11.25 mg 3-month formulation are in the same range as observed for the IM injection [ 30 , 31 ].…”

Section: Triptorelin As Adtmentioning

confidence: 99%

“…Recently, SC administration of triptorelin pamoate 11.25 mg 3-month formulation was shown to achieve castrate levels of testosterone within 4 weeks of the first injection in 97.6% of men with locally advanced or metastatic prostate cancer [ 31 ]. Treated patients reached testosterone levels of <50 ng/dl after a median of 22 days and maintained castration until study end at 26 weeks (in 96.6% of those who achieved castration at 4 weeks) [ 31 ]. Most patients (77.7%) also met the stringent castration definition of testosterone concentration <20 ng/dl at 4 weeks, increasing to 90.8% after 26 weeks.…”

Section: Triptorelin As Adtmentioning

confidence: 99%

See 2 more Smart Citations

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

Merseburger

Hupe

2016

Adv Ther

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, have been developed to provide improved flexibility and convenience for the patient. Head-to-head studies of GnRH agonists are lacking in the field of prostate cancer. Despite the inevitable progression to castration-resistant prostate cancer (CRPC) in most patients receiving ADT, monitoring of testosterone levels needs to improve in routine practice and physicians should not overlook the benefits of continued ADT in their patients when introducing one of the various new treatment options for CRPC. For improved survival outcomes, there remains a need to tailor ADT treatment regimens, novel hormonal agents and chemotherapy according to the individual patient with advanced prostate cancer.

show abstract

Section: Triptorelin As Adtmentioning

confidence: 99%

Section: Triptorelin As Adtmentioning

confidence: 99%

Section: Triptorelin As Adtmentioning

confidence: 99%

See 1 more Smart Citation

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

Merseburger

Hupe

2016

Adv Ther

View full text Add to dashboard Cite

show abstract

“…In addition, rising PSA levels are commonly used to diagnose CRPC in the clinic, with a minority of oncologists or urologists citing testosterone levels as an additional marker, according to a European survey 5. Clinical trials have continued to use the <1.7 nmol/L testosterone cutoff, although some studies are starting to explore lower cutoff values 12. A recent trial found that gonadotropin-releasing hormone agonist therapy was associated with a 90.0% probability of maintaining serum testosterone levels of <0.7 nmol/L up to 26 weeks, compared with a 96.0% probability of testosterone levels of <1.7 nmol/L (95% CI, 85.0–95.0 and 92.0–99.0, respectively) 12…”

Section: Defining Medical Castration With Adtmentioning

confidence: 99%

Androgen deprivation therapy as backbone therapy in the management of prostate cancer

Merseburger¹,

Alcaraz²,

Klot³

2016

OTT

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is well established as a backbone therapy for metastatic prostate cancer (mPCa), and both European and American guidelines emphasize the importance of maintaining ADT after progression to metastatic castration-resistant prostate cancer (CRPC). However, the use of ADT varies widely in clinical practice despite these recommendations. Both research and development of increasingly precise assay technologies have improved our understanding of androgen production and signaling, and the recent data have suggested that a new serum testosterone cutoff value of <0.7 nmol/L should be employed. Most clinical trials to date have used the historical 1.7 nmol/L cutoff, but the <0.7 nmol/L cutoff has been associated with improved patient outcomes. Combining agents with different mechanisms of action to achieve intense androgen blockade may improve survival both before and after progression to CRPC. Data suggest that this intensive approach to androgen deprivation could delay the transition to CPRC and hence improve survival dramatically. Various combinations of backbone ADT with chemotherapy or radiotherapy are under investigation. Administration of ADT is established in patients with intermediate or high-risk localized prostate cancer (PCa) receiving radiotherapy with curative intent. This article reviews the current and potential role of ADT as backbone therapy in both hormone-sensitive PCa and CRPC with a focus on mPCa.

show abstract

“…Likewise, the route of administration (i.m. or s.c.) appears to have minimal impact upon the pharmacological suppression of testosterone [19]. The pharmacokinetic properties of these formulations are summarised in Table 1 [12,[20][21][22][23][24][25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Bolton

Lynch

2018

BJU International

View full text Add to dashboard Cite

To review direct comparative studies of the gonadotrophin-releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'triptorelin' and 'goserelin', and (iii) 'prostate cancer' and 'goserelin' and 'leuprorelin', without time restriction. Duplicates were deleted. Relevant conference abstracts were also screened. A total of 16 direct comparative trials were identified: 12 reported on efficacy outcomes, four on safety/tolerability, and five on the convenience of administration/user perceptions. These studies are restricted in terms of patient numbers, formulations assessed, and endpoints measured; none were adequately powered for survival outcome measures. Studies reporting on efficacy endpoints did not show major differences in the ability of these GnRH agonists to reduce levels of testosterone or prostate-specific antigen. Some studies suggest differences in short- or long-term testosterone control, the rate of injection site adverse events, and patient/healthcare professional perceptions, but definitive conclusions cannot be drawn from the existing evidence. Few direct comparative trials of GnRH agonists have been conducted. Whilst GnRH agonists provide a similar castration effect, there is not enough evidence to show that GnRH agonists are equivalent.

show abstract

Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer

Abstract: This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer.

Cited by 10 publications

References 25 publications

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

Androgen deprivation therapy as backbone therapy in the management of prostate cancer

Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

Contact Info

Product

Resources

About